Introduction

Cysteinyl leukotrienes (cysLTs) (LTC₄, LTD₄, LTE₄) are an important class of proinflammatory lipid molecules that are thought to mediate many of the principal features of bronchial asthma such as bronchial constriction, airway hyperresponsiveness and leukocyte trafficking. They are synthesized in vivo by immunocompetent cells such as mast cells, eosinophils, basophils and monocytes/macrophages [1]. Upon cell activation, intracellular phospholipase A₂ releases arachidonic acid from membrane phospholipids. 5-lipoxygenase subsequently converts arachidonic acid to the unstable intermediate LTA₄, which is then conjugated to reduced glutathione by leukotriene C4 synthase to form LTC₄. After transport to extracellular space, LTC₄ is converted to LTD₄ and then to the terminal product LTE₄, the most stable and the most abundant cysLT in biological fluids.

The biological actions of cysLTs are mediated by two currently identified G-protein coupled receptors (GPCR): CysLT type 1 receptor (CysLT₁) and type 2 receptor (CysLT₂). They differ in binding affinities for different cysLTs. CysLT₁ is recognised as a high-affinity receptor for LTD₄, whereas CysLT₂ binds LTC₄ and LTD₄ with similar affinity [2,3,4,5]. LTE₄ has long been believed to be the final and least active metabolite of cysLTs, with low affinity for binding to the classical receptors and lowest functional agonistic potency in comparison to LTC₄ and LTD₄ [6].

Inhaled LTD₄ has been shown to elevate the numbers of sputum eosinophils in subjects with asthma [7]. However, it was LTE₄ that was shown to be the most potent cysLT in eliciting influx of inflammatory cells such as eosinophils and basophils into bronchial mucosa of asthmatic subjects [8,9]. These preferential agonist functions of LTE₄ were not explained by pharmacological properties of CysLT₁ or CysLT₂. Similarly, there is still no explanation for the comparable potency of LTE₄ in comparison to LTC₄ and LTD₄ in eliciting a dermal wheal and flare reaction in human skin [10] and for equally effective contraction of human bronchi in vitro by all cysLTs [11]. All of the above data strongly suggests the existence of one or more specific LTE₄ receptors that have not been identified to date. The potential existence of such a receptor has been recently demonstrated [12]. In a knock-out murine model, vascular permeability induced by intradermal injection of LTE₄ in mice lacking both CysLT₁ and CysLT₂ exceeded the response to LTC₄ and LTD₄, suggesting the presence of another cysLT receptor that responds preferentially to LTE₄. LTE₄ was 64-fold more potent in CysLT₁/CysLT₂ double deficient mice than in wild type mice, revealing an inhibitory negative regulation of the novel LTE₄ receptor by the two known receptors. It was also found that the pre-treatment of
double deficient mice with a selective CysLT antagonist did not inhibit, but increased even further the permeability response to all cysLTs.

Interestingly, recent in silico modelling and in vitro studies suggested that LTE₄ may be a ligand for an ADP receptor, P₂Y₁₂ when heterologously expressed as a fusion protein with human Gₛ₄₁₆ [13]. Further evidence for the interaction of LTE₄ with the purinergic receptor P₂Y₁₂ was provided by Paruchuri et al. who showed that P₂Y₁₂ was required for LTE₄-mediated pulmonary inflammation [14]. Mice lacking the classical cysLT receptors maintained LTE₄-induced eosinophilia, goblet cell metaplasia and IL-13 expression in response to low-dose of aerosolized allergen but P₂Y₁₂ knock-out and platelet-depleted mice [a cell type highly expressing P₂Y₁₂] showed a substantial loss in those functions. Although direct binding of labelled LTE₄ to P₂Y₁₂ could not be demonstrated, data from cells overexpressing P₂Y₁₂ indicated that the presence of P₂Y₁₂ is required for signalling and activation by LTE₄.

Human P₂Y₁₂ has been cloned and characterised with ADP as its natural agonist [15]. It has been shown to couple to Gₛ₄ and signal in response to ADP by inhibiting adenylate cyclase activity and cAMP generation in human platelets and when heterologously expressed [16]. To address the question whether LTE₄ is also a direct agonist for human P₂Y₁₂ or activates P₂Y₁₂ signalling through GPCR heterodimer interactions we characterised responsiveness to cysLTs in recombinant models of cell over-expressing P₂Y₁₂ and in platelets, primary human cells constitutively expressing P₂Y₁₂.

Materials and Methods

Reagents

Leukotrienes (LTE₄, LTD₄ and LTE₄) were purchased from Cayman Chemical (Ann Arbor, Mich). ADP, 2-methylthio-adenosine-5'-diphosphate (2MeS-ADP), prostaglandin E₁ (PGE₁), isoproterenol, forskolin, 3-Isobutyl-1-methylxanthine (IBMX) and calcium ionophore (A23187) were purchased from Sigma-Aldrich (Dorset, UK).

Cell Culture

HEK293 cells were cultured in high glucose (4500 mg/L) DMEM supplemented with 2 mmol/L glutamine, 10% fetal bovine serum and Penicillin/Streptomycin (50 units/ml/50 μg/ml) (all Life Technologies, UK) in a humidified 5% CO₂ 37°C incubator. Cells were passaged every 3–4 days replacing all medium with fresh cell culture medium.

Transient Transfection of HEK293 Cells

HEK293 cells cultured to above 60% confluence were transiently transfected with a mixture of Lipofectamine 2000 (Life Technologies) and the following plasmids as indicated: pcDNA3.1-human CysLT₁, pcDNA3.1-human CysLT₂, pcDNA3.1-human P₂Y₁₂, pcDNA3.1-3xHA human P₂Y₁₂, pcDNA3.1-human Gₛ₄₁₆, pcDNA3.1-3xHA human ADRB2 (all the Missouri S&T cDNA Resource Center, Rolla, Mo) and pCMV6-Kan/Neo- mouse P₂Y₁₂ (Origene Technologies) in serum-free medium (Opti-MEM, Life Technologies) according to manufacturer’s protocol. After incubation the transfection medium was removed and HEK293 cells were cultured for 36 hours in standard culture medium at 37°C in a humidified 5% CO₂ incubator.

Preparation of Platelet-rich Plasma

The study was approved by the Research Ethics Committee of Guy’s Hospital. Blood was collected over citrate-dextrose solution (ACD, 6:1) from patients who had provided written informed consent prior to any procedure. Platelet-rich plasma (PRP) was prepared by centrifugation at 150 g for 15 minutes at room temperature. PRP was centrifuged for a further 5 minutes to reduce erythrocyte contamination.

Calcium Mobilisation Assay

Calcium mobilisation assays were conducted using FLIPR calcium 4 assay kit (Molecular Devices, Sunnyvale, CA) as described previously [17,18]. HEK293 cells [1.5×10⁵/well] were plated into poly-D-lysine coated 96 well plates in RPMI 1640 supplemented with 10 mmol/L HEPES. After a 5-hour incubation, cells were incubated for 1 hour with FLIPR loading buffer prior to addition of ligand and fluorescent intensity was measured at 37°C using a Flexstation 3 (Molecular Devices). Controls included medium control with ethanol for leukotriene stimulations.

PRP was washed in modified Tyrode’s buffer (pH 6.2, 150 mmol/L NaCl, 3 mmol/L KCl, 5 mmol/L glucose, 1 mmol/L MgCl₂, 10 mmol/L HEPES, 0.1% BSA) supplemented with 0.5 μmol/L PGE₁. Platelets (2×10⁶/well) were plated into 96-well plates in modified Tyrode’s buffer supplemented with 1.26 mmol/L CaCl₂ and incubated for 30 minutes with FLIPR loading buffer supplemented with 2.5 mmol/L probenecid and fluorescence was measured using a Flexstation 3. Results were analysed with SoftMax Pro Software (Molecular Devices).

Analysis of Receptor Surface Expression

Washed transfected HEK293 cells were stained with an Alexa Fluor 488 conjugated anti-HA monoclonal antibody (Clone 16B12, Covance, Ca) that recognises the HA epitope that is N-terminally located on the receptors of interest. Analysis was performed on a FACScalibur with CellQuest Pro software (BD Biosciences).

cAMP Accumulation Assay

Intracellular cAMP accumulation was analysed in HEK293 cells using the Cyclic AMP assay kit (Meso Scale Discovery, Gaithersburg, MD, USA) following manufacturer’s protocols. HEK293 cells with added IBMX (1 μmol/L) were plated on anti-cAMP coated MULTI-ARRAY 96-well small spot plates (MDS), stimulated with forskolin and agonists for 15 minutes as indicated, lysed and run on the ImageSector 6000 (Meso Scale Discovery). Results were analysed using MSD workbench software.

Intracellular cAMP accumulation was analysed in PRP using the HitHunter® cAMP XS+ assay kit (DiscoverX, UK) following manufacturer’s protocols. PRP was centrifuged at 1000 g for 10 minutes and washed three times with pre-chilled DPBS supplemented with 2 mmol/L EDTA. Platelets (5×10⁶/well) suspended in DPBS supplemented with 1 mmol/L EDTA and 1 μmol/L IBMX, were plated on a 96-well plate, stimulated with forskolin and other agonists for 20 minutes as indicated and incubated with detection reagents. Luminescent signal was measured 4 hours after lysis using a Flexstation 3. Results were analysed with SoftMax Pro Software.

β-arrestin Recruitment Assay

Analysis of β-arrestin recruitment was conducted using a Pathhunter® cExpress β-arrestin kit (DiscoverX) following manufacturer’s protocols. In this system, the GPCR and β-arrestin are fused to two fragments of β-galactosidase and the interaction of the two proteins results in an enzymatic reaction. In brief, CHO cells stably transfected with the C-terminally modified human
(mouse) P2Y₁₂ and with the β-arrestin, N-terminally tagged with deletion mutant of β-galactosidase, were seeded on 96-well plates in OCC medium for a 48 hour recovery period at 37°C. Cells were stimulated for 90 minutes at 37°C as indicated and then incubated with detection reagents for a further 90 minutes at room temperature. Luminescent signal, which is directly related to the recruitment of β-arrestin to P2Y₁₂ in the assay, was measured using a Flexstation 3.

Analysis of Platelet Activation by Flow Cytometry

Whole peripheral blood drawn over ACD (6:1) was stimulated immediately after collection for 10 minutes at room temperature. 5 μL of blood was directly stained with monoclonal antibodies against CD61 (APC, clone VI-PL2) and CD62P (PE, clone Psel.KO2.3) or appropriate isotype controls (all eBiosciences). Cells gated in the platelet population were analysed for platelet activation using a FACScalibur with CellQuest Pro software (BD Biosciences).

CCL5/RANTES ELISA

PRP supplemented with 0.5 μmol/L PGE₁ was centrifuged at 1000 g for 10 minutes and washed three times with pre-warmed modified Tyrode’s buffer supplemented with 0.5 μmol/L PGE₁. PRP was stimulated for 15 minutes with indicated agonists and CCL5 was measured in supernatants using a CCL5/RANTES duo set kit (R&D Systems, UK) following manufacturer’s protocol. Optical density was recorded on Anthos hI III (Anthos Labtech) using Stingray (DazDaq) software. Measurements at 450 nm were corrected by measurement at 578 nm and concentrations of RANTES/CCL5 were generated from the standard curve.

Statistical Analysis

Data were analysed by means of one- or two-way ANOVA using GraphPad Prism software (GraphPad, La Jolla, Ca). Differences were considered significant at a p-value of less than 0.05.

Figure 1. Effect of LTE₄ on calcium mobilisation in h-P2Y₁₂ overexpression model. HEK293 cells were transiently transfected with indicated vectors and intracellular responses recorded. (A) [h-CysLT₁] and (B) [h-CysLT₂] transfectants stimulated with indicated concentrations of LTC₄, LTD₄ and LTE₄, N=6. (C) Flow cytometry analysis of h-P2Y₁₂ protein surface expression in [h-P2Y₁₂] and [Empty] transfectants using an anti-HA antibody, representative of three experiments. (D) [h-P2Y₁₂] and [Empty] transfectants stimulated with ADP or LTE₄, N=9. Results (A), (B) and (D) represented as peak intracellular calcium response, relative fluorescence units (RFU), mean ± S.E.M.

doi:10.1371/journal.pone.0058305.g001
Results

CysLT-mediated Calcium Mobilisation in Models of Transiently Expressed CysLT₁, CysLT₂ and P2Y₁₂

To ascertain whether LTE₄ could mediate signal transduction through the P2Y₁₂ receptor, a model of heterologous receptor expression was established in HEK293 cells. These cells do not natively express any known classical cysLT receptors or P2Y₁₂ and when unmodified they do not respond to cysLT stimulation. To validate this model, constructs expressing human (h)-CysLT₁ and h-CysLT₂ were transiently transfected into separate HEK293 populations as previously described [5]. The transfectants were stimulated with exogenous LTC₄, LTD₄ and LTE₄ and their intracellular calcium responses were measured using FLIPR Calcium 4 assay kit and a FlexStation 3, showing similar receptor potency as reported previously, with LTE₄ having the lowest potency for calcium mobilisation in comparison to LTC₄ and LTD₄. (Fig. 1A–B) [19]. Constructs expressing h-P2Y₁₂ with N-terminal 3xHA tag were then transiently transfected into HEK293 cells and surface expression was verified by flow cytometry (Fig. 1C). On stimulation with exogenous cysLTs or ADP, the known natural ligand for h-P2Y₁₂, no difference was found in intracellular calcium flux responses between the h-P2Y₁₂ transfectants and controls transfected with empty vectors (Fig. 1D), although calcium response to ADP was observed reflecting constitutive expression of other purinergic receptors and showing that h-P2Y₁₂ signal transduction does not occur through calcium mobilisation in this model.

LTE₄-mediated Calcium Mobilisation in Gα₁₆ co-transfection Models

Co-transfections of G-protein coupled receptors (GPCRs) and the fusion protein, Gα16, have been reported previously to directly activate phospholipase C and calcium signalling [20]. To demonstrate the effectiveness of this approach in our recombinant model we overexpressed human β₂ adrenergic (h-ADRβ₂) receptor and stimulated with isoproterenol. A construct encoding h-ADRβ₂ with N-terminal 3xHA tag was transiently co-transfected with a construct containing h-Gα₁₆ into HEK293 cells and surface expression of the receptor was verified by flow cytometry (Fig. 2A). On stimulation with exogenous isoproterenol, h-ADRβ₂ transfectants overexpressing h-Gα₁₆ were able to produce a statistically significant (p = 0.0003; 2-way ANOVA) increase in calcium flux compared to h-ADRβ₂ transfectants showing that h-Gα₁₆ has the potential to modulate GPCR signal transduction in our HEK293 heterologous expression model (Fig. 2B).

Constructs containing tagged h-P2Y₁₂ were then co-transfected with h-Gα₁₆ and receptor surface expression was confirmed by flow cytometry (Fig. 2A). These transfectants were also able to show statistically significant increases in calcium responses to ADP (p = 0.0022; 2-way ANOVA) and its more stable derivative, 2-MeS-ADP (p = 0.019; 2-way ANOVA), compared to control transfectants (fig. 2C–D). Negligible increases in calcium flux were observed upon LTE₄ stimulation of the h-P2Y₁₂+ h-Gα₁₆ transfectants (Fig. 2C–D) and upon stimulation with LTC₄ and LTD₄ (data not shown).

P2Y₁₂-induced Intracellular cAMP Signalling

Human P2Y₁₂ has been shown to signal physiologically through Gα₁ and by inhibition of intracellular cAMP generation. To analyse this potential signalling pathway, h-P2Y₁₂ transfectants were stimulated with forskolin to activate adenylyl cyclase and to increase cAMP levels, together with ADP or cysLTs and intracellular cAMP was measured using a competitive immunoassay. ADP induced a significant, concentration dependent inhibition of forskolin induced cAMP in h-P2Y₁₂ transfectants, while LTE₄ treatment showed no statistically significant difference in cAMP accumulation over a range of 0.5–300 nmol/L concentrations, from the empty vector transfectants (Fig. 3A). This confirms that h-P2Y₁₂ does not signal directly through the coupling of either to Gα₁ or Gα₁ upon LTE₄ stimulation. We could also exclude Gα₁₂ signalling in our model as no change in cAMP levels was observed when h-P2Y₁₂ transfected cells were stimulated with ADP or cysLTs alone (not shown).

P2Y₁₂-induced β-arrestin Signalling

Recruitment of β-arrestin is another activation event that can be analysed as a measure of GPCR activation. Until recently, an agonist’s efficacy for β-arrestin recruitment was believed to be proportional to its efficacy for G-protein activities. However, it has been demonstrated that “biased ligands” can selectively activate β-arrestin function and elicit specific biological effects [21]. To address the question of β-arrestin specific signalling induced by LTE₄, C-terminally modified h-P2Y₁₂ stably transfected into CHO cells with β-arrestin N-terminally tagged with a deletion mutant of β-galactosidase were stimulated with either 2-MeS-ADP or cysLTs and processed according to manufacturer’s protocol (Fig. 3B). Stimulation with 2-MeS-ADP induced a concentration dependent luminescent signal relating to the recruitment of β-arrestin to the h-P2Y₁₂ receptor. Stimulation with LTE₄ and other cysLTs showed no significant increase in signal suggesting a lack of β-arrestin pathway activation by leukotrienes. Collectively these observations show that cysLTs do not induce G-protein dependent or independent signalling pathways directly through h-P2Y₁₂ indicating that h-P2Y₁₂ is not a cysLT receptor.

LTE₄-mediated Signalling through Mouse P2Y₁₂

The ability of LTE₄ to mediate pulmonary inflammation has been shown to be dependent on P2Y₁₂ expression in mouse models, as indicated by Paruchuri et al. [14]. Strong evidence shows that on removal of the P2Y₁₂ receptor, either by knock down or by platelet depletion, the influx of inflammatory cells to the mouse lung can be significantly diminished. Although these findings are contradictory to our results, the lack of LTE₄ mediated signalling in our recombinant model could be due to species differences as mouse (m)-P2Y₁₂ shares only 89% homology to its human derivative [22]. To test this possibility a construct encoding m-P2Y₁₂ were transiently transfected into HEK293 cells and stimulated with exogenous 2-MeS-ADP, LTC₄, LTD₄ or LTE₄. Although a robust calcium flux was detected in response to 2-MeS-ADP stimulation, it did not differ in comparison to empty vector control transfectants and no response, similar to that of the human P2Y₁₂ (Fig. 1D), was recorded for cysLT stimulation (data not shown). Co-transfections of m-P2Y₁₂ and Gα₁₆ were then employed to direct any signal transduction to activate calcium mobilisation. 2-MeS-ADP stimulation of these co-transfectants was able to induce a statistically significant increase in calcium mobilisation compared to the control transfectants (Fig. 4A) indicating that h-Gα₁₆ is sufficiently able to direct the signalling pathway of m-P2Y₁₂. No specific calcium flux was observed on stimulation of these co-transfectants with LTE₄ (Fig. 4A).

To determine whether LTE₄ could activate m-P2Y₁₂ via the recruitment of β-arrestin, stable CHO cell transfectants of C-terminally modified m-P2Y₁₂ and N-terminally tagged β-arrestin were stimulated with either 2-MeS-ADP or cysLT. Although stimulation with 2-MeS-ADP induced a dose-dependent luminescent signal, LTE₄ stimulation produced negligible effects (Fig. 4B). These results show that m-P2Y₁₂ signalling responses towards cysLT stimulation are similar to that of h-P2Y₁₂.

P2Y₁₂ Does Not Respond to Cysteinyl Leukotrienes

This confirms that h-P2Y₁₂ does not signal directly through the coupling of either to Gα₁ or Gα₁ upon LTE₄ stimulation. We could also exclude Gα₁₂ signalling in our model as no change in cAMP levels was observed when h-P2Y₁₂ transfected cells were stimulated with ADP or cysLTs alone (not shown).
LTE₄-induced Signalling and Cell Activation in Human Platelets

Physiologically, the signalling capability of P2Y₁₂ is highly modulated by another ADP purinergic receptor, P2Y₁ [23]. Signal modulation, whether this is through heterodimerisation or reciprocal cross-talk, allows the potentiation of signalling responses from both P2Y₁₂ and P2Y₁. To determine whether the importance of P2Y₁₂ in LTE₄ mediated pulmonary inflammation in vivo could be due to such interactions or heterodimerisation of GPCRs, isolated human platelets, one of very few cell types that highly express P2Y₁₂, were stimulated with 2-MeS-ADP and LTE₄ and their intracellular signalling responses were analysed. A robust calcium mobilisation in a dose dependent manner and a statistically significant inhibition of cAMP were generated by 2-MeS-ADP stimulation (Fig. 5A–B) indicating that platelets isolated from whole blood were functionally intact and are responsive to P2Y₁₂ agonists. LTE₄ stimulation was unable to generate any calcium mobilisation and no significant inhibition of cAMP was observed (Fig. 5A–B) which is in agreement with the recombinant model data (Fig. 1D and 3A).

Activated platelets enter into an aggregation cascade where adhesion molecules are upregulated on the cell surface and range of stored mediators are released to enhance this process. To address the question whether cysLTs are able to activate platelets through P2Y₁₂ or physiologically expressed receptor heterodimers, platelet activation measured by expression of P-selectin (CD62P) and release of stored chemokine CCL5 (RANTES) were analysed. Whole blood was stimulated with either ADP, 2-MeS-ADP or cysLTs and CD62P expression was measured by flow cytometry on the CD61⁺ population of human platelets (Fig. 5C). Whereas a robust upregulation of CD61 was observed after ADP or 2-MeS-ADP stimulation, no such a response was observed for LTE₄ or other cysLTs (data not shown) which was observed for activated platelets stimulated with calcium ionophore or ADP released increased amounts of CCL5, no such a response was observed.
Figure 3. Effect of LTE4 stimulation on cAMP and β-arrestin signalling pathways. Intracellular cAMP concentrations and β-arrestin recruitment was analysed in models of transiently transfected HEK293 or stably modified CHO cells, respectively. (A) [h-P2Y12] and [Empty] transfectants were stimulated with forskolin and either ADP or LTE4, N = 6, data expressed as % of forskolin stimulated control. (B) CHO cells expressing h-P2Y12 and β-arrestin were stimulated with either 2-MeS-ADP or LTE4, N = 9, expressed as relative luminescence units (RLU). Data represented as mean ± S.E.M. Two-way ANOVA with Bonferroni post-hoc test, *p < 0.05.

doi:10.1371/journal.pone.0058305.g003

Figure 4. Effect of LTE4 stimulation on calcium and β-arrestin signalling pathways in mouse P2Y12 transfectants. HEK293 cells were transiently transfected with indicated vectors and intracellular calcium responses recorded. (A) [m-P2Y12 + Gα16] and [Empty + Gα16] transfectants were stimulated with LTE4 and 2-MeS-ADP, N = 9, 2-way ANOVA between 2-MeS-ADP responses p = 0.0101. (B) CHO cells stably expressing m-P2Y12 and β-arrestin were stimulated with either 2-MeS-ADP or LTE4, N = 9. Data presented as mean ± S.E.M.

doi:10.1371/journal.pone.0058305.g004
identified upon stimulation with LTE₄ (Fig. 5E) or other cysLTs (data not shown).

Discussion

This study highlights the complexities in leukotriene receptor biology and leukotriene signalling pathways involved in the immune response in chronic inflammatory diseases, such as atherosclerosis, asthma and rhinosinusitis. Ever since the elucidation and cloning of the two human cysLT receptors, CysLT₁ and CysLT₂, LTE₄ has become the forgotten mediator in cysLT biology [6]. Its apparent weak efficacy in recombinant systems, poor binding affinities compared to LTC₄ and LTD₄, and the availability of selective CysLT₁ antagonists, sidelined LTE₄ as an...
important target for basic and clinical research. Recent studies have re-examined the role of LTE4 in pulmonary inflammation in relation to P2Y12 (a receptor proposed as a putative LTE4 receptor) [13]. Low dose OVA-induced allergic lung inflammation murine models lacking P2Y12 functionality either by knock down, platelet depletion or receptor antagonism, exhibited a substantial reduction in LTE4 mediated pulmonary inflammation, a phenomenon not observed in CysLT1/CysLT2 double knock out mice [14]. We undertook this study to determine whether these observations were specifically related to direct P2Y12-LTE4 interactions, therefore determining whether P2Y12 was in fact a cysteinyl leukotriene receptor.

Firstly, we established the heterologous expression model in which the recombinant receptors of interest could be transiently overexpressed in HEK293 cells. The best understood cysteinyl leukotriene receptor signalling pathway couples to G\(\alpha_q\), thus functional validation of the expression model was carried out by analysing intracellular calcium mobilisation. The pattern of ligand functional validation of the expression model was carried out by sensitive to the specific CysLT1 antagonist, MK-571 (data not shown), therefore validating the expression model. Unsurprisingly, calcium mobilisation was not induced by cysteinyl leukotriene stimulation of P2Y12 transfectants, as the purinergic receptor has been well characterised as a GPCR that mainly activates G\(\alpha_i\) signalling pathways, affecting intracellular Ca\(^{2+}\) levels. However, the lack of LTE4 calcium mobilisation in P2Y12 transfectants co-expressing the G\(\alpha_q\) protein was in stark contrast with the initial study by Nonaka et al. identifying LTE4 as a surrogate ligand for P2Y12 [13]. They showed that LTE4, but not LTC4 or LTD4, was mimicked in transfectants containing the mouse version of the 16 protein was in stark contrast with the initial observations was shown by the negligible effect of LTE4 and other cysteinyl leukotrienes on cAMP accumulation and \(\beta\)-arrestin recruitment (Fig. 3), two intracellular signalling pathways being potently activated in the same assays by known P2Y12 agonists, ADP and 2-MeS-ADP. This lack of LTE4 induced signalling was mimicked in transfectants containing the mouse version of the P2Y12 receptor (Fig. 4) suggesting that the deficiency in signalling responses was not merely a human phenomenon and was independent of species variation. As no direct P2Y12 signalling upon cysteLTs stimulation was observed in any of our recombinant experiments, we decided to address another possibility that LTE4 activates cells through another GPCR forming a heterodimer with P2Y12 in vivo. Platelets are one of very few cell types that functionally express P2Y12 and platelet depletion potently inhibited LTE4 mediated pulmonary inflammation (9) so we used human platelets to verify whether these cells are able to respond to cysteLTs. No specific responses to LTE4 or other leukotrienes were observed when intracellular signalling (calcium, cAMP) as well as cell activation (P-selectin expression and CCL5/RANTES release) was measured. In contrast, human platelets strongly responded to known P2Y12 agonists and non-specific activators in those assays showing that cells were able to respond to appropriate stimulations implying that platelets are not a direct target for leukotrienes.

If platelets and P2Y12 do not respond to LTE4 as our data suggests, a question arises how observations from Paruchuri et al. on LTE4 mediated pulmonary inflammation may be explained? Our hypothesis is that LTE4 must activate specific receptors present on cells other than platelets, potentially structural cells such as endothelial cells, smooth muscle cells or tissue resident cells i.e. mast cells. Upon LTE4 activation, such cells would produce (release) mediator(s) activating platelets or platelet-adherent leukocytes, facilitating cell adhesion to endothelium, cell activation and migration to tissue and as a result enhancing inflammatory responses. Platelet involvement in proinflammatory reactions, especially in pulmonary inflammation observed in asthma has been of increased interest recently. Clinical evidence has demonstrated increases in circulating platelets in atopic asthmatics, as well as increases in leukocyte-platelet aggregates after allergen challenge [24,25,26]. Recent advancements in the field have shown the direct importance of platelets in leukocyte recruitment and airway remodelling in allergic inflammation [14,27,28]. Therefore the reduction in LTE4 mediated pulmonary inflammation seen in the study by Paruchuri et al. could be directly due to loss of P2Y12 functionality rather than LTE4 specific phenomenon [14]. However the studies of Paruchuri et al. and Maekawa et al. have elegantly highlighted that LTE4 signalling can occur independently to the classical cysLT receptors, CysLT1 and CysLT2 [14,29] proving that LTE4 preferentially signals via another as yet unidentified cysLT receptor.

In conclusion, our study strongly suggests that LTE4 does not activate signalling either solely through P2Y12 or through P2Y12 being modulated by another receptor. The requirement to discover the true receptor for LTE4 is still very apparent so that more effective anti-leukotriene therapies can be developed for the treatment of asthma.

**Author Contributions**

Conceived and designed the experiments: THL, GW. Performed the experiments: HRF, EF. Analyzed the data: HRF EF GW. Contributed reagents/materials/analysis tools: DJC. Wrote the paper: HRF THL DJC GW.

**References**

1. Peters-Golden M, Henderson WR (2007) Mechanisms of disease: Leukotrienes. N Engl J Med 357: 1841–1854.
2. Lynch K, O’Neill G, Liu G, Im D, Somyer N, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789–793.
3. Heise CE, O’Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, et al. (2000) Characterization of the human cysteinyl leukotriene receptor 2 protein. J Biol Chem 275: 30531–30536.
4. Woensmeker G, Chen L-Y, Nagineni S, Aabathy S, Harry A, et al. (2007) ION-gamma induces cysteinyl leukotriene receptor 2 expression and enhances the responsiveness of human endothelial cells to cysteinyl leukotrienes. J Immunol 178: 5262–5270.
5. Woensmeker G, Chen L-Y, Nagineni S, Kern S, Barb J, et al. (2008) Leukotriene D-4 induces gene expression in human monocytes through cysteinyl leukotrienes type 1 receptor. J Allergy Clin Immunol 121: 215–221.
6. Lee TH, Woensmeker G, Farooque SP (2009) Leukotriene E-4: Perspective on the forgotten mediator. J Allergy Clin Immunol 124: 417–421.
7. Diamant Z, Hildemann JT, van Rensen EL, Callenbach PM, Veselic-Charvat M, et al. (1997) The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 155: 1247–1253.
8. Laitinen LA, Laitinen A, Haahela T, Vilka V, Spur BW, et al. (1993) Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 341: 989–990.
9. Goureau GM, Parameswaran KN, Watson RM, O’Byrne PM (2003) Inhaled leukotriene E4, but not leukotriene D4, increases airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 164: 1495–1500.
10. Soter NA, Lewis RA, Corey EJ, Austen KF (1983) Local effects of synthetic peptidoleukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea. J Pharmacol Exp Ther 252: 87–95.
11. Buckner CK, Fedyna JS, Robertson JL, Will JA, England DM, et al. (1990) An examination of the influence of the epithelium on contractile responses to peptideplukotrienes and blockade by ICI 204,219 in isolated guinea pig trachea and human intralobal airways. J Pharmacol Exp Ther 252: 77–85.
12. Markawa A, Kanaoka Y, Xing W, Austen KF (2008) Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A 105: 16695–16700.
13. Nonaka Y, Hiramoto T, Fujita N (2005) Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337: 281–288.
14. Parnichuri S, Tashimo H, Feng CL, Markawa A, Xing W, et al. (2009) Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 206: 2543–2555.
15. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, et al. (2001) Identification of the platelet ADP receptor targeted by anti-thrombotic drugs. Nature 409: 202–207.
16. Baurand A, Eddy A, Hechler B, Kauflenstein G, Galai J, et al. (2005) Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 67: 721–733.
17. Chen LY, Eberlein M, Alsaaty S, Martinez-Anton A, Barb J, et al. (2011) Cooperative and redundant signaling of leukotriene B-4 and leukotriene D-4 in human monocytes. Allergy 66: 1304–1311.
18. Parmenter CN, Fuerst E, McDonald J, Bowen H, Lee TH, et al. (2012) Human TH2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1. J Allergy Clin Immunol 129: 1136–1142.
19. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55: 195–227.
20. Offermanns S, Simon MI (1995) G-alpha(15) and G-alpha(16) couple a wide variety of receptors to phospholipase-C. J Biol Chem 270: 15175–15180.
21. Luttrell LM, Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115: 455–465.
22. Altschul SF, Madden TL, Schaffer AA, Zhang JH, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402.
23. Hardy AR, Jones ML, Mundell SJ, Poole AW (2004) Reciprocal cross-talk between P2Y(1) and P2Y(12) receptors at the level of calcium signaling in human platelets. Blood 104: 1745–1752.
24. Gresele P, Donorini M, Selli ML, Iannacci L, Canino S, et al. (1993) Altered platelet-function associated with the bronchial hyperresponsiveness accompanying nocturnal asthma. J Allergy Clin Immunol 91: 894–902.
25. Kowal K, Pampuch A, Kowal-Bielecka O, DuBuske LM, Bodzentyn-Lukaszyk A (2006) Platelet activation in allergic asthma patients during allergen challenge with Dermatophagoides pteronyssinus. Clin Exp Allergy 36: 426–432.
26. Yamamoto H, Nagata M, Tabe K, Kimura I, Kiuchi H, et al. (1993) The evidence of platelet activation in bronchial asthma. J Allergy Clin Immunol 91: 79–87.
27. Pitchford SC, Yano H, Lever R, Raffo-Vasquez Y, Ciferri S, et al. (2003) Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 112: 109–118.
28. Pitchford SC, Raffo-Vasquez Y, Sousa A, Momi S, Gresele P, et al. (2004) Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood 103: 639–647.
29. Markawa A, Kanaoka Y, Xing W, Austen K (2008) Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci USA 105: 16695–16700.